Bone-Targeted IL-6 Conjugates for Sustained Muscle Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The decline in muscle function with age, particularly due to the short half-life of osteocalcin, limits exercise capacity and is challenging to address with continuous infusion methods.
Innovation Solution
Development of an IL-6 family cytokine-bisphosphonate conjugate that enhances Interleukin-6 (IL) release or activity, specifically through conjugating bisphosphonates to IL-6 family cytokines like IL-6, Leptin, IL-11, CNTF, LIF, OSM, CT-1, CLC, or IL-27, to enhance muscle function and exercise capacity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If osteocalcin is continuously infused to maintain muscle function, then muscle function is improved, but the complexity of the device increases due to requirement of implanted pump
Solution Approach 1:
The patent uses an IL-6 family cytokine-bisphosphonate conjugate as an intermediary substance that mediates between bone and muscle. The conjugate binds to bone via the bisphosphonate moiety and releases IL-6 cytokine that acts on muscle tissue, eliminating the need for direct osteocalcin infusion pumps while maintaining muscle function.
Solution Approach 2:
Instead of directly administering osteocalcin, the patent creates a conjugate that copies the beneficial effects of osteocalcin through IL-6 signaling. The IL-6 family cytokine-bisphosphonate conjugate reproduces the muscle-protective effects of osteocalcin without requiring the same delivery infrastructure.
2Reliability
If osteocalcin levels are replenished to restore exercise capacity, then exercise capacity is improved, but the duration of action is limited due to short half-life of osteocalcin
Solution Approach 1:
The bisphosphonate component of the conjugate binds irreversibly or with very long duration to bone mineral, anchoring the IL-6 cytokine at the target site. This preliminary binding action ensures sustained release of IL-6 over extended periods, overcoming the short half-life limitation of protein-based therapeutics like osteocalcin.
Solution Approach 2:
The patent uses IL-6 family cytokines which can produce effects that exceed or partially replicate the biological activity of osteocalcin. The conjugate system provides excessive IL-6 signaling relative to physiological levels, ensuring durable muscle function improvement despite the short half-life of the protein component.
3Reliability
If IL-6 family cytokine-bisphosphonate conjugate is used to enhance IL-6 release, then muscle function is improved, but the manufacturing complexity increases due to conjugation process
Solution Approach 1:
The conjugate is designed as two distinct functional modules: a bisphosphonate moiety for bone targeting and an IL-6 family cytokine for muscle activation. This segmentation allows each component to be optimized and synthesized separately using established methods, then combined through relatively simple conjugation chemistry, reducing overall manufacturing complexity.
Data Source
AI summary
Methods for treating muscle loss and exercise capacity pathologies by controlling osteocalcin release, and compositions therefor, are provided.